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Abstract
Background: The B9, CRF07_BC and CRF01_AE are the predominant HIV-1 subtypes in China. It is essential to determine
their baseline susceptibility to HIV entry inhibitors before these drugs are used in China.
Methodology/Principal Findings: The baseline susceptibility of 14 representative HIV-1 isolates (5 CRF07_BC, 4 CRF01_AE,
and 5 B9), most of which were R5 viruses, obtained from drug-naı ¨ve patients to HIV entry inhibitors, including two fusion
inhibitors (enfuvirtide and C34), two CCR5 antagonists (maraviroc and TAK779) and one CXCR4 antagonist (AMD3100), were
determined by virus inhibition assay. The sequences of their env genes were amplified and analyzed. These isolates
possessed similar susceptibility to C34, but they exhibited different sensitivity to enfuvirtide, maraviroc or TAK779.
CRF07_BC isolates, which carried polymorphisms of A578T and V583I in the N-terminal heptad repeat and E630Q, E662A,
K665S, A667K and S668N in the C-terminal heptad repeat of gp41, were about 5-fold less sensitive than B9 and CRF01_AE
isolates to enfuvirtide. Subtype B9 isolates with a unique polymorphism site of F317W in V3 loop, were about 4- to 5-fold
more sensitive than CRF07_BC and CRF01_AE isolates to maraviroc and TAK779. AMD3100 at the concentration as high as
5 mM exhibited no significant inhibitory activity against any of the isolates tested.
Conclusion: Our results suggest that there are significant differences in baseline susceptibility to HIV entry inhibitors among
the predominant HIV-1 subtypes in China and the differences may partly result from the naturally occurring polymorphisms
in these subtypes. This study provides useful information for rational design of optimal therapeutic regimens for HIV-1-
infected patients in China.
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Introduction
The human immunodeficiency virus type 1 (HIV-1) can be
classified to three major groups, M (major), O (outlier) and N (non-
M non-O or new). The M group, which has caused the vast
majority of HIV-1 infections worldwide, can be further divided
into several subtypes, including A–D, F–H, J and K, as well as
several circulating and unique recombinant forms (CRFs and
URFs) [1,2]. The greatest genetic diversity of HIV-1 subtypes has
been found in China. Among them, HIV-1 subtype B9 (also known
as Thai B), CRF07_BC (BC) and CRF01_AE (AE) are the
predominant circulating viruses in China [3,4].
HIV-1 infection is established after viral entry into the target cell
[5]. The molecules involved in HIV-1 entry are attractive targets
for developing antiviral therapeutics [6–8]. Based on drug targets,
the HIV-1 entry inhibitors can be classified into three groups,
including i) attachment inhibitors (e.g., NBD556 and BMS378806)
that block the interaction between the HIV-1 envelope glycopro-
tein (Env) surface subunit gp120 and CD4 receptor by targeting to
the CD4-binding site on gp120; ii) co-receptor antagonists, which
block the interaction ligand between gp120 and CCR5 (e.g., UK-
427857 and TAK779) or CXCR4 (e.g., AMD3100); and iii) HIV-
1 fusion inhibitors (such as T20 and C34) [9,10]. T20 (brand
name: Fuzeon; generic name: enfuvirtide) and UK-427857 (brand
name: Selzentry; generic name: maraviroc) were approved by the
US FDA in 2003 and 2007 as the first and second HIV-1 entry
inhibitors, respectively, for treatment of HIV-1-infected patients
who fail to respond to the current antiretroviral drugs (ARVs)
[11,12].
The Chinese national AIDS treatment program, including the
free treatment with nucleotide and nucleoside reverse transcriptase
inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors
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mortality rate among HIV-1 infected patients [13,14]. However,
the continuous emergence of HIV-1 resistance to NRTIs and
NNRTIs has resulted in high failure rate in clinical applications of
these anti-HIV drugs [15–17]. In order to improve the outcome of
the treatment and to prevent the transmission of resistant strains, it
is urgently needed to design new effective treatment regimens for
those who have failed to respond to the first line ARVs. HIV entry
inhibitors could be the first choice for these patients in China.
However, it is unclear whether these HIV entry inhibitors are also
highly effective against the predominant HIV-1 strains circulating
in China since none of the US FDA-approved HIV entry
inhibitors has ever been tested in clinics in China.
The present study aims to test the baseline susceptibility of the
predominant HIV-1 subtypes circulating in China to HIV entry
inhibitors and characterize the genotype polymorphisms in these
subtypes. This study is expected to provide a clearer understanding
of the natural resistance of the predominant viruses to HIV entry
inhibitors and valuable information for rational design of
treatment regiments containing HIV entry inhibitors for HIV-
infected patients in China and other Asian countries.
Results
Characteristics of the study population and HIV-1
variants
We isolated 26 viral strains with in vitro infectivity from
peripheral blood mononuclear cells (PBMCs) of the HIV-1-
infected patients. But in this study, we only used in this study 14
strains isolated from the patients who had not used ARVs before,
including 11 males and 3 females (averaging 37.6 years old). They
were infected by HIV-1 through three different pathways,
including former plasma donors (FPD) from Anhui Province
(n=5), injection drug users (IDUs) from Xinjiang province (n=5)
and the victims of sexually transmitted infections (STIs) from
Beijing (n=4). As shown in Table 1, the average viral load was
5.1460.97 log copies/mL (ranged from 4 to 6.2 log copies/mL),
and the average CD4 count was 4156185 cells/mL (ranged from
75 to 628 cells/mL). The infection strains belong to different HIV-
1 subtypes, including 5 B9, 5 CRF07_BC and 4 CRF01_AE
isolates (Table 1). All of the isolated strains used CCR5 as co-
receptor, including 2 dual tropic (R5/X4-tropic) isolates. The
phylogenetic tree was then constructed (Fig. 1).
Phenotypic susceptibility of different HIV-1 subtypes to
HIV entry inhibitors
TZM-bl cells were infected with different subtypes of HIV-1
isolates in the presence of various concentrations of the HIV entry
inhibitors (enfuvirtide, C34, TAK779, maraviroc and AMD3100).
Luciferase activity was measured for evaluation of the viral
infectivity and IC50 value for each inhibitor was calculated. All the
isolates were susceptible to HIV fusion inhibitors and CCR5
antagonists with average IC50 values of 60666, 19612, 78659
and 1.4061.36 nM for enfuvirtide, C34, TAK779 and maraviroc,
respectively. The three subtypes of HIV-1 isolates possessed
similar susceptibility to C34, while they exhibited different
sensitivity to enfuvirtide, TAK779 and maraviroc. CRF07_BC
isolates were about 5-fold less sensitive than CRF01_AE, B9 and B
isolates to enfuvirtide, whereas the subtype B9 and B isolates were
4- to 5-fold more sensitive than CRF07_BC and CRF01_AE to
TAK779 and maraviroc. It is noticeable that there was a high
variation in the data obtained from testing different strains in the
same subtype, which may result from the presence of random
error in viral titration and susceptibility testing, the gene diversity
and polymorphism in the same subtype, and the relatively small
sample size. However, the difference of susceptibilities to
enfuvirtide between CRF07_BC and CRF01_AE or B9 isolates
and that to TAK779 and maraviroc between subtype B9 and
CRF07_BC or CRF01_AE were statistically significant (P,0.05
or 0.01) when the Wilcoxon rank sum test was used. The CXCR4
antagonist AMD3100 at the concentration as high as 5 mM
exhibited no significant inhibitory activity against any of the
isolates tested, including 2 dual-tropic (X4/R5) strains (Table 2).
The polymorphism analysis of the HIV-1 Env gp41 and
gp120
The amino acid sequences of the viral Env gp41 and gp120
were analyzed and compared with the corresponding reference
Table 1. Characteristics of the HIV-1 clinical isolates that are predominantly circulating in China.
Virus Sex Age CD4 counts (/ml) CD8 counts (/ml) Viral load (log10) Coreceptor Subtype
CBJB257 F 27 376 1,122 4.0 R5 CRF 07_BC
XJDC6291 M 35 155 1,596 6.1 R5 CRF 07_BC
CBJB256 M 46 75 352 6.0 R5 CRF 07_BC
XJDC6371 M 34 590 1,955 5.5 R5 CRF 07_BC
XJDC6331 M 38 319 1,435 6.2 R5 CRF 07_BC
CYM033 M 28 397 918 3.0 R5 CRF 01_AE
BJMSM543 M 28 613 766 5.8 R5 CRF 01_AE
CYM015 M 32 628 961 5.2 R5 CRF 01_AE
BJMSM376 M 54 598 1,198 5.9 R5 CRF 01_AE
020100259 M 32 506 1,292 5.7 R5 B9
020100104 F 52 421 943 3.9 X4/R5 B9
020100968 M 38 440 1,093 5.2 R5 B9
020100096 F 44 141 468 4.4 R5 B9
020100311 M 39 552 1,159 5.0 X4/R5 B9
doi:10.1371/journal.pone.0017605.t001
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possibly related with the natural resistance to the HIV entry
inhibitors (Fig. 2). There was no visible substitution in the GIV
tripeptide sequence (residues 547–549) of gp41 N-terminal heptad
repeat (NHR), the primary determinant of viral resistance to
enfuvirtide [18]. The polymorphism at position 553 was N553S in
all the CRFs or N553R in most B9 isolates. The polymorphism at
position 580 was I580V in all the isolates. Interestingly, the
polymorphisms of A578T and V583I were only found in
CRF07_BC strains, which were about 5-fold less sensitive to
enfuvirtide than CRF01_AE and subtype B9 strains (Table 2). The
polymorphisms of Q591K and L592F were found in all the
CRF01_AE isolates.
The C-terminal heptad repeat (CHR) sequences of different
CRFs were highly polymorphic, compared with the B9 subtype. In
the region of residues 638–673 of CHR, which corresponds to the
sequence of enfuvirtide, substitutions at positions 640, 641, 643,
644 and 658 were commonly recorded across the three different
subtypes. The polymorphisms of E630Q, E662A, K665S, A667K
and S668N in CHR of gp41 were found only in the CRF07_BC
isolates.
High polymorphism was seen in the V3 region of gp120 from
those B9, BC and AE isolates (Fig. 2). Polymorphisms of R306S,
R311I, R315Q, V318Y, T319A, I320T, K323I, N326D, and
M317I appeared in most of the CRF07_BC isolates, while the
substitutions of N300S and K305T could only be seen in all the
CRF01_AE isolates. Notably, the unique polymorphism of F317W
was found in all subtype B9 isolates, which were about 4- to 5-fold
more sensitive to CCR5 inhibitors, maraviroc and TAK779.
Therefore, the two dominant polymorphism of R315Q and
F317W in the V3 region of gp120 in CRF07_BC and CRF01_AE
isolates might be related to their lower susceptibility to maraviroc
and TAK779.
Discussion
Since 2003, free ARVs, consisting of four NRTIs, one NNRTI,
and one protease inhibitor, have been provided to rural residents
and the urban poor with HIV infection in China [19,20]. It has
been shown that combinational use of these ARVs indeed results
in significant reduction of mortality of the HIV/AIDS patients in
China [13,14]. However, increasingly more HIV/AIDS patients
have failed to respond to these ARVs because of the emergence of
drug-resistant HIV-1 variants [21,22]. Therefore, it is essential to
add some new classes of anti-HIV drugs into the ARV regimens
used in China.
In recent years, two HIV entry inhibitors, enfuvirtide that
targets the HIV-1 gp41 [11,12] and maraviroc, a CXCR5
antagonist [23,24] were approved by the US FDA for clinical
use, but neither of them has been tested in China. Therefore, it is
reasonable to question whether these HIV entry inhibitors are
effective against the HIV-1 subtypes that are predominantly
circulating in China. In this study, we intended to investigate the
susceptibility of the HIV-1 subtypes that are predominantly
circulating in China, including subtypes B9, CRF07_BC, and
CRF01_AE, to the two newly marketed HIV entry inhibitors,
Figure 1. Phylogenetic analysis of HIV-1 env genes. The viral env sequences were obtained by PCR analysis of plasma samples of 14 HIV-1
infected and treatment naı ¨ve patients. ‘‘&’’, ‘‘m’’, ‘‘X’’ represent the env sequence of CRF07_BC, CRF01_AE and B9 strains tested respectively.
doi:10.1371/journal.pone.0017605.g001
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targeting HIV entry steps.
Here we found that these three subtypes of HIV-1 isolates
possessed similar susceptibility to C34, but exhibited different
sensitivity to enfuvirtide. CRF07_BC isolates were about 4- to 5-
fold less sensitive to enfuvirtide than subtype B9 isolates (P=0.004)
and CRF01_AE isolates (P=0.01). The NHR region in the gp41
ectodomain is the main target of enfuvirtide, C34, sifuvirtide (a
C34 analog peptide under Phase II clinical trials), and other CHR
peptides [25–28]. In the early in vitro study, enfuvirtide-induced
viral resistance was associated with mutations in the GIV motif
(residues 547–549) [18]. In the subsequent in vivo and in vitro
studies, the determinant of resistance to enfuvirtide, sifuvirtide and
C34 was mapped to the NHR domain of residues 547–556, which
are critical for NHR and CHR interaction to form six-helix bundle
core structure [29–32]. Some mutations in CHR (e.g., N637K,
N648K, and S649A) may compensate for the loss in fitness and
restore viral fusion kinetics while retaining the drug resistance
[29–33].
To investigate why CRF07_BC isolates were less sensitive than
subtype B9 and CRF01_AE isolates to enfuvirtide, we analyzed the
gp41 NHR sequences. But we did not find any substitutions in the
GIV motif and the residues 547–556 region in NHR related to
viral resistance to enfuvirtide [18,29–32], which is contrary to the
report by Leung et al [34] who identified the G36D mutation in
19.4% of HARRT-experienced patients and 20.5% of ART-naı ¨ve
patients in Hong Kong. The only polymorphism in this region is
N553S, which was shown to be present in about 15% of HIV-1
isolates with non-decreased enfuvirtide susceptibility [35]. Inter-
estingly, we found two unique polymorphisms beyond the region
of residues 547–556 in NHR, A578T and V583I, which are
unique to the CRF07_BC isolates (Fig. 2B). Further study is
needed to investigate whether the polymorphisms A578T and
V583I are associated with the natural viral resistance to
enfuvirtide.
Different from the conserved NHR sequence, CHR of gp41 is
highly polymorphic, particularly in the region corresponding to
the T-20 synthetic peptide (residues 638–673). In this region,
CRF07_BC is more polymorphic than CRF01_AE and B9,
including A578T, V580I, E630Q, L641T, E662A, K665S,
A667K and S668N. Whether these naturally occurring polymor-
phisms in the gp41 CHR of CRF07_BC strains are associated with
their natural resistance to HIV entry inhibitors is unknown.
Eggink et al [29] has proposed four mechanisms of viral resistance
to enfuvirtide, including reduced contact, steric obstruction,
electrostatic repulsion, and electrostatic attraction. For example,
replacement of the non-charged residue in CHR with a charged
residue, or vice visa, may cause electrostatic repulsion or
attraction, resulting non-optimal helix packing and/or docking.
In this study, we found several such substitutions, including
E662A, K665S, and A667K, which are only present in the
CRF07_BC. But it is unclear whether or not these substitutions
are associated with the resistance of CRF07_BC to enfuvirtide.
We found that subtype B9 isolates were about 4- to 5-fold more
sensitive than CRF07_BC isolates to TAK779 (P=0.009) and
maraviroc (P=0.024), respectively. The two dual tropic viruses
(020100104 and 020100311) of subtype B9 were also very sensitive
to TAK779 and maraviroc. Recent studies have demonstrated
Table 2. Baseline susceptibility of HIV-1 clinical isolates that are predominantly circulating in China to HIV entry inhibitors.
Virus HIV-1 entry inhibitors targeting
NHR of gp41 CCR5 CXCR4
enfuvirtide C34 TAK779 maraviroc AMD3100
Subtype CRF 07_BC
CBJB257 0.07660.017 0.00960.002 0.19960.160 1.44460.157 .5
XJDC6291 0.11460.077 0.01960.001 0.11260.023 1.72960.103 .5
CBJB256 0.05460.014 0.01660.005 0.06160.047 1.14060.120 .5
XJDC6371 0.16960.029 0.01460.001 0.07860.036 4.94861.495 .5
XJDC6331 0.22660.030 0.04260.013 0.09260.023 2.25460.127 .5
Mean 0.12860.033 0.02060.004 0.10860.058 2.30360.400 .5
Subtype CRF 01_AE
CYM033 0.02360.007 0.02660.005 0.16260.049 2.97861.141 .5
BJMSM543 0.05260.027 0.01760.005 0.04160.008 0.51560.137 .5
CYM015 0.01360.001 0.00560.000 0.15160.030 0.26160.033 .5
BJMSM376 0.01160.005 0.01360.003 0.07560.013 2.36960.38 .5
Mean 0.02560.010 0.01560.003 0.10760.025 1.53160.423 .5
Subtype B9
020100259 0.03460.019 0.05260.017 0.01460.002 0.51060.000 .5
020100104 0.01360.003 0.01260.003 0.04060.003 0.20460.021 .5
020100968 0.03660.003 0.01360.005 0.01260.004 0.39960.121 .5
020100096 0.01260.001 0.01660.000 0.01660.000 0.26060.000 .5
020100311 0.01160.005 0.01360.003 0.03460.007 0.58460.054 .5
Mean 0.02160.006 0.02160.007 0.02360.003 0.39160.039 .5
Each sample was tested in triplicate, and each experiment was repeated twice. IC50 (mM, except nM for maraviroc) data are presented as means 6 standard deviations.
doi:10.1371/journal.pone.0017605.t002
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PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e17605Figure 2. Alignment of the HIV-1 gp160. The V3 region and CHR sequences of the different CRFs and subtype B9 were highly polymorphic,
compared to the B9 subtype. The NHR sequences were relatively conserved. HXB2-LAI-IIIB-BRU (Acc K03455), CN.97, C54, CN.97.97CNGX_6F,
CM240_ACC_U54772 and RL42 were used as reference sequences.
doi:10.1371/journal.pone.0017605.g002
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(dual-X4), while others are much more efficient in using the CCR5
(dual-R5) [36,37]. Our preliminary result indicated that these two
dual tropic viruses mainly used CCR5 co-receptor to enter cell,
suggesting that they are dual-R5 strains. Polymorphic substitutions
R311L/I, R315Q, A316T/V/M, T319A/R were found in V3
region of all CRFs and subtype B9. Multiple studies have
demonstrated that the natural variation in the V3 loop affects
the sensitivity of the HIV entry inhibitors, especially the
substitutions in position 318 and 319. In our study, two dominant
amino acid changes in V3 loop on gp120, R315Q and T319A, in
CRF07_BC isolates may be associated with lower susceptibility to
maraviroc, which is in agreement with several recent studies
[38–40]. Subtype B9 isolates were also more sensitive than
CRF01_AE isolates to TAK779 (P=0.013) and maraviroc
(P=0.036), which may be associated with substitutions N300S,
K305T and Q328K in V3 loop in gp120 of all CRF01_AE
isolates. However, we could not exclude the possible maraviroc-
resistant substitutions outside the V3 loop since the regions of the
HIV-1 Env responsible for resistance to CCR5 inhibitors have
mapped to not only V3 loop [41], but also other regions of the
gp120 [42], or even the regions in gp41 [43].
AMD3100 exhibited no significant inhibitory activity against all
the isolates tested even at 5 mM, which is more than 10,000-fold to
the sensitive X4 strain. Though a paper reported that AMD3100
could inhibit infection by dual-tropic (X4/R5) strains [44], we did
not find its inhibitory activity on the two dual-tropic strains
isolated in this study. In a phase I/II clinical trial, AMD3100 was
shown to significantly reduce HIV RNA levels in patients who
harbored pure X4-tropic virus but not in the remaining subjects
who harbored either dual-tropic or R5-tropic viruses [45]. Huang
and colleagues reported that AMD3100 was able to suppress X4-
tropic variants in vivo. The suppression of CXCR4-using variants
by AMD3100 is dependent on both the tropism composition of the
virus population and the efficiency of CXCR4 usage of individual
variants. We thus assumed that the dual-tropic viruses isolated in
our study may be more efficient in using CCR5 than CXCR4 to
infect target cells.
In summary, CRF07_BC isolates were much less sensitive than
B9 and CRF01_AE isolates to HIV fusion inhibitor, enfuvirtide,
while subtype B9 isolates were more susceptible than CRF07_BC
and CRF01_AE isolates to CCR5 antagonists, maraviroc and
TAK779. The baseline resistance to the HIV entry inhibitors may
be associated with the naturally occurring polymorphisms in these
subtypes. This study thus provides useful information for rational
design of optimal therapeutic regimens to treat patients infected
with different HIV-1 subtypes.
Methods
Study population
The HIV-1 CRF07_BC and B9 isolates were isolated from the
blood of pre-selected HIV-1-infected patients, who participated in
a multicenter AIDS Cohort Study in China during 2003–2005
[46]. HIV-1 CRF_01AE isolates were from local HIV-1-positive
individuals in Beijing, who were recruited to the AIDS Cohort
Study in 2006–2008 as subjects infected through sexual transmis-
sion. The plasma viral loads of blood samples collected from 14
selected antiretroviral treatment-naı ¨ve HIV-1 infected patients
were measured with COBAS AMPLICORTM techniques and
analyzer (Roche Diagnostics, Alameda, CA). CD4
+ T lymphocyte
counts in whole blood were quantitated by flow cytometry using
reagents and equipment provided by Becton Dickinson Biosci-
ences (San Jose, CA). This study was approved by the Institutional
Research Ethics Community, China CDC (IRB00002276), and all
subjects signed informed consent forms before blood collection.
HIV entry inhibitors
AMD3100, TAK779 and maraviroc were obtained from the
National Institutes of Health AIDS Research and Reference
Reagent Program. C34 and T-20 were synthesized by a standard
solid-phase Fmoc (N-(9-fluorenyl-) methoxycarbonyl) method in
the MicroChemistry Laboratory of the New York Blood Center
(New York, NY).
Isolation of HIV-1 from PBMCs from HIV-1-infected
patients
PBMCs from patient’s whole blood were isolated by standard
density gradient centrifugation using Ficoll-Paque PLUS density
gradient medium (GE Healthcare Bio-Sciences Corp., Piscataway,
NJ). The isolated PBMCs were cocultured with phytohemagglu-
tinin-stimulated PBMCs from at least 2 HIV-1 seronegative blood
donors in RPMI-1640 medium supplemented with 10% fetal calf
serum, 100 U/mL penicillin, 100 mg/mL streptomycin, 2.9 mg/
mL L-glutamine and 100 IU rhIL-2 (Roche Diagnostics) as
previously described [46]. The p24 antigen levels of culture
supernatants were measured once per week for 4 weeks using a
commercial enzyme-linked immunosorbent assay (ELISA) kit
according to the manufacturer’s recommendations (Bio-Merieux,
Marcy-l’Etoile, France). Virus culture supernatants with p24
.1 ng/mL were aliquoted and stored in liquid nitrogen until use
[47].
HIV-1 Env sequence analysis
Viral RNA was extracted from virus isolated from HIV-1
patients using RNA extraction kit (Qiagen, Hilden, Germany).
The viral RNA was used to generate reverse strand cDNA by RT-
PCR kit (Invitrogen, Carlsbad, CA). The sequences of the Env
region were then amplified by a nested polymerase chain reaction
(nest-PCR) as previously described [48]. The outer primers for
clades B9, CRF07_BC, and CRF01_AE were HZBOB/HZBOE
pair, HZBCOB/HZBCOE pair and HZAEOB/HZAEOE pair,
respectively, which yield approximately 3100-base pair (bp)
products. The inner primers for clades B9, BC, and AE were
HZBIB/HZBIE pair, HZBCIB/HZBCIE pair and HZAEIB/
HZAEIE pair, respectively, which yield 2970-bp products [48].
The amplified fragments were identified on an agarose gel by
electrophoresis, purified with QIAquick Gel Extraction kit
(QIAGEN), directly sequenced using an ABI 377 Sequencer
(Applied Biosciences) and then analyzed using Vector NCI
software.
Susceptibility assay to HIV entry inhibitors based on
TZM-bl cells
The antiviral activity of HIV entry inhibitors against HIV-1
isolates from treatment-naı ¨ve patients was determined using
TZM-b1 cells as previously described [49]. The 50% tissue
culture infectious dose (TCID50) of a single thawed aliquot of each
virus was determined in TZM-bl cells as described previously [50].
TZM-bl cells were seeded (10
4/well) and cultured in a 96-well
tissue culture plate overnight. The following day, 100 TCID50
diluted virus was added per well in the absence or presence of
drugs with five series dilutions (5, 1, 0.1, 0.01 and 0.001 mM for
enfuvirtide, C34, TAK779 and AMD3100; 1, 0.1, 0.01, 0.001 and
0.0001 mM for maraviroc). After further incubation at 37uC for
48 hours, the luciferase activity was measured using luciferase
assay regents (Promega) and a Luminescence Counter (Perkin-
HIV-1 Subtype Susceptibility to Entry Inhibitors
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tration of drug that inhibits 50% viral replication (IC50) was
determined by nonlinear regression using GraphPad Prism 5.01.
Mean IC50s were calculated using all replicates for each virus and
are expressed as mean6 SD.
Statistical Methods and Analysis
The Wilcoxon rank sum test was applied to pairwise
comparisons to determine whether the observed differences
between IC50 for different subtype were statistically significant.
The value of 0.05 was used as the criterion for statistical
significance.
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